contact us
An interim analysis of mid-stage data on Concert Pharmaceuticals’ $CNCE JAK inhibitor for alopecia may have thinned its potential against Pfizer’s $PFE rival drugs in development.
Do Not Allow Advertisers to Use My Personal information
